Insulin-like growth factor-I inhibits insulin and amylin secretion in conscious rats.

Human recombinant insulin-like growth factor-I (IGF-I) exerts insulin-like antidiabetic properties in vitro and in vivo. To determine the effects of IGF-I infusion on insulin and amylin release, plasma glucose of freely moving undisturbed rats was constantly maintained at 13.9 mmol/liter by variable glucose infusion for 120 min in three groups of fasted Sprague-Dawley rats (hyperglycemic clamp technique). Group A, vehicle infusion (control group); group B, bolus 0.39 nmol plus 0.39 nmol/h IGF-I continously; and group C, bolus 1.96 nmol plus 1.96 nmol/h IGF-I continuously. During the steady-state phase of the experiment, IGF-I dose dependently reduced plasma insulin (pmol/liter: A, 718 +/- 58; B, 613 +/- 35, NS vs. A; C, 408 +/- 21, P < 0.01 vs. A; dose-response effect: P < 0.0001), plasma amylin (pmol/liter: A, 10.2 +/- 0.6; B, 8.8 +/- 0.5, NS vs. A; C, 5.8 +/- 0.4, P < 0.01 vs. A; dose-response effect: P < 0.0001), and net glucose uptake (mumol/kg.min: A, 188 +/- 12; B, 160 +/- 12, NS vs. A; C, 134 +/- 7, P < 0.01 vs. A; dose-response effect: P < 0.0025). At the same time, the ratio of plasma insulin/plasma amylin (mol/mol: A, 72 +/- 6; B, 71 +/- 5; C, 74 +/- 9; NS), the ratio of net glucose uptake/plasma insulin (mumol/kg.min per pmol/liter: A, 0.28 +/- 0.03; B, 0.27 +/- 0.02; C, 0.36 +/- 0.04; NS), and glycogen content of liver, heart, and various hindlimb muscles remained unaffected. The results demonstrate that IGF-I is a potent inhibitor of insulin and amylin release in healthy rats exposed to hyperglycemia and suggest that IGF-I infusion inhibits hormone secretion from pancreatic beta cells at infusion rates that do not affect insulin-stimulated glucose uptake by peripheral tissues.

[1]  M. Roden,et al.  Islet amyloid polypeptide inhibits insulin secretion in conscious rats. , 1994, The American journal of physiology.

[2]  K. Minaker,et al.  Effects of recombinant human IGF-I on glucose and leucine kinetics in men. , 1993, The American journal of physiology.

[3]  M. Roden,et al.  Insulin resistance caused by amylin in conscious rats is independent of induced hypocalcemia and fades during long-term exposure. , 1993, Acta endocrinologica.

[4]  W. Riesen,et al.  Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. , 1992, The Journal of clinical investigation.

[5]  F. Horber,et al.  Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans. , 1992, The Journal of clinical endocrinology and metabolism.

[6]  C. Tipton,et al.  Effects of prior exercise on the action of insulin-like growth factor I in skeletal muscle. , 1992, The American journal of physiology.

[7]  A. Hoffman,et al.  Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans. , 1992, The Journal of clinical endocrinology and metabolism.

[8]  H. Ursprung,et al.  Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. , 1992, The Journal of clinical investigation.

[9]  B. Ludvik,et al.  Decrease of Stimulated Amylin Release Precedes Impairment of Insulin Secretion in Type II Diabetes , 1991, Diabetes.

[10]  M. Frölich,et al.  Whole body and hepatic insulin action in normal, starved, and diabetic rats. , 1991, The American journal of physiology.

[11]  L. Rossetti,et al.  In Vivo Insulin Resistance Induced by Amylin Primarily Through Inhibition of Insulin-Stimulated Glycogen Synthesis in Skeletal Muscle , 1991, Diabetes.

[12]  R. DeFronzo,et al.  Metabolic Effects of IGF-I in Diabetic Rats , 1991, Diabetes.

[13]  R. Silvestre,et al.  Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas , 1990, Regulatory Peptides.

[14]  Michael W. Schwartz,et al.  Evidence of Cosecretion of Islet Amyloid Polypeptide and Insulin by β-Cells , 1990, Diabetes.

[15]  J. Leahy,et al.  Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion. , 1990, Endocrinology.

[16]  E. Froesch,et al.  Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Pipeleers,et al.  Evidence for the presence of type I insulin-like growth factor receptors on rat pancreatic A and B cells. , 1987, Endocrinology.

[18]  E. Froesch,et al.  Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. , 1987, The New England journal of medicine.

[19]  E. Froesch,et al.  Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. , 1986, The Journal of clinical investigation.

[20]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[21]  A. Steffens.  A method for frequent sampling of blood and continuous infusion of fluids in the rat without disturbing the animal , 1969 .